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Abstract
Background: In order to predict long-term prognosis and define individual treatment modalities for patients with
oral squamous cell carcinoma (OSCC), more reliable tumor biomarkers are needed during the pretreatment workup
period. The present study aimed to identify more reliable immunohistochemical tumor prognostic markers in the
pretreatment biopsy specimens of patients with OSCC.
Methods: We selected 57 patients who were diagnosed with primary OSCC through histopathological analysis.
Pretreatment biopsy specimens were immunohistochemically analyzed for the transcription factor NANOG, cancer
stem cell marker CD44, and mutant tumor protein 53 (mutant p53). The immunostaining patterns were assessed for
their association with the clinicopathological features of OSCC and overall survival rates.
Results: Late tumor stage, positive neck node metastasis, and high-grade differentiation were associated with
significantly poorer survival rates. Enhanced expression of NANOG and mutant p53 positivity were significantly
associated with clinically late-stage tumors, positive neck node metastasis, histologically high-grade tumors, and
poor overall survival rates. OSCCs with strong co-detection of NANOG and mutant p53 were linked to significantly
lower survival rates than those with both weak NANOG expression and p53 negativity. Increased expression of
CD44 had a limited correlation with unfavorable clinicopathological features.
Conclusion: High expression of NANOG and positive expression of mutant p53 in the pretreatment biopsy
specimens of patients with OSCC were associated with poor survival rates and unfavorable clinicopathological
features. These results demonstrate that NANOG, mutant p53, and CD44 could be used as immunohistochemical
markers in the pretreatment specimens of OSCC. In particular, analysis for co-expression of NANOG and mutant p53
should be made highly available as a tool for prognosis and selecting individual treatment modalities.
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Background
Oral squamous cell carcinoma (OSCC) is a common ma-
lignant tumor of the head and neck region; however, pa-
tients with OSCC have a 5-year survival rate of less than
50 %. The traditional TNM staging and histopathological
grading systems do not enable physicians to accurately pre-
dict a tumor’s aggressiveness or select treatment modalities
on an individual basis [1]. Therefore, research has been
underway to investigate more effective and definitive
tumor prognostic markers for patients with OSCC [2, 3].
As the cancer stem cell (CSC) hypothesis has become one
of the predominant theories explaining the tumor-
initiating capacity and heterogeneity of tumor cells, various
stem cell markers have been studied to determine their
correlation with clinicopathological tumor features and
long-term prognosis [4–8].
The early transcription factors NANOG, OCT4, and
SOX2, which play pivotal roles in the maintenance of
pluripotency and self-renewal ability in both embryonic
and adult stem cells, have also been reported as key
regulation factors in the CSCs of head and neck squa-
mous cell carcinoma (HNSCC) [7, 8]. High expression
of NANOG and OCT4 has been positively correlated
with histologically high-grade carcinomas and clinically
poor prognosis [7–10]. CD44 was the first CSC marker
described in a solid malignancy [5], and a high frequency
of CD44 positive cells in HNSCC strongly correlates
with recurrence and tumor aggressiveness [11]. Tumor
protein 53 (p53) is considered a traditional tumor bio-
marker in squamous cell carcinoma (SCC); however, its
usefulness as a prognostic indicator remains unclear [1].
Wild-type p53 protein is barely detectable in normal
tissues because of its short half-life of approximately
20 min. [12] However, the tumor suppressor gene p53 is
mutated in approximately 40–60 % of OSCC cases, and
this mutant p53 plays an important role in tumor devel-
opment and progression [12, 13]. Interestingly, mutant
p53 protein is usually detectable via immunohistochem-
istry (IHC) [14, 15].
In order to predict long-term prognosis and define in-
dividual treatment modalities for patients with OSCC,
more reliable tumor biomarkers (including immunohis-
tochemical prognostic markers) are needed during the
pretreatment workup period. The present study aimed
to investigate the expression of various tumor markers
via IHC, including stem cell and tumor-related bio-
markers, to identify more reliable prognostic markers in
OSCC biopsy specimens collected prior to cancer treat-
ment. In the present study, we observed a positive
correlation between the clinicopathological features of
OSCCs and the immunohistochemical expression pat-
terns of NANOG, human mutant p53, and CD44. In
addition, the immunostaining intensities of these marker
proteins (NANOG and mutant p53) were positively




Between 2004 and 2014, a total 92 patients were diagnosed
with OSCC in the Department of Oral and Maxillofacial
Surgery of Gyeongsang National University Hospital
(GNUH) based on the histopathological analysis of biopsy
specimens collected prior to cancer treatment. Among
them, 57 patients with primary OSCC (excluding patients
with metastatic and recurrent cancers; 36 men and 21
women) were selected for the present study. The inclusion
criteria were patients who agreed to participate in the
study, completed at least 3 months of follow-up after
undergoing pretreatment biopsy, and had sufficient tissue
volume in the pretreatment biopsy specimen to perform
immunohistochemical staining. The medical records of the
selected patients were retrospectively analyzed. Informed
consent for the use of their tissue specimens was obtained
from all patients, and this study was approved by the Ethic
Committee for Clinical Research at GNUH (GNUH IRB-
2012-09-004-002). IHC was performed on the pretreat-
ment biopsy specimens of the 57 patients, which were
obtained from the periphery of the tumor margin with a
minimum length of 5 mm and minimum width and depth
2 mm, to analyze the relationship between protein expres-
sion patterns and clinicopathological tumor features. The
duration of follow-up for the 57 patients ranged from 3 to
127 months, with a mean of 35.9 months. The patients
were clinically evaluated according to the TNM classifica-
tion system developed by the American Joint Committee
on Cancer (7th edition, 2010) for tumor stage and neck
node metastasis, and overall survival rates were also deter-
mined. Biopsy specimens were histopathologically graded,
and tumors were categorized as well, moderately, or poorly
differentiated according to the WHO classification of
tumors [16].
Immunohistochemical analysis of biopsy specimens
Biopsy specimens were fixed in 10 % neutral buffered for-
malin for 24 h, embedded in a paraffin block, sliced into 4-
μm sections and mounted on SuperfrostPlus microscope
slides (Fisher Scientific, Rochester, NY, USA). The sections
were maintained at room temperature for 12 h. After hy-
dration, IHC for NANOG, CD44, and mutant p53 was per-
formed using an automated immunostainer (BenchMark
XT, Ventana Medical System Inc., Tucson, AZ, USA), and
visualization was conducted using the Ultraview DAB kit
(Ventana Medical System Inc.) according to the manufac-
turer’s protocol. For immunostaining of the three marker
proteins, we used rabbit monoclonal antibodies (Abcam™,
Cambridge, UK). The dilution rate and lot numbers of the
primary antibodies are summarized in Table 1. Briefly,
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sections were deparaffinized using EZ Prep solution; then
CC1 standard (pH 8.4 buffer contained Tris/Borate/EDTA)
was applied for antigen retrieval for 60 min at 100 °C. The
slides were incubated at 37 °C for 4 min with a DAB in-
hibitor (3 % H2O2) to block endogenous peroxidase activ-
ity. Then, slides were incubated with the primary antibody
at 37 °C for 32 min, followed by incubation with the
secondary antibody (Universal HRP Multimer) for 8 min at
37 °C. Slides were treated with DAB+ H2O2 substrate for
8 min followed by hematoxylin II and bluing reagent at
37 °C for nuclear counterstaining. For negative controls,
only incubation with the secondary antibody was per-
formed, omitting any incubation with a primary antibody,
in sections from the same specimens under the same con-
ditions. In addition, human embryonic urinary bladder and
skin carcinoma tissues were used as positive controls for
NANOG, CD44, and mutant p53, respectively, according
to the antibody manufacturer’s recommendations.
Tissue slices were semi-quantitatively analyzed for anti-
body deposition in cellular components by two pathologists
who were blinded to the study information. Based on a
previously reported method with modification [10],
positive immunostaining of NANOG and CD44 was
scored by the combination of intensity (0, negative
staining; 1, weak staining; 2, moderate staining; and 3,
strong staining) and the percentage of positively stained
tumor cells in high-power fields (0, negative; 1, <25 %;
2, 25–50 %; 3, 51–75 %; and 4, >75 %). The sum of the
staining intensity and percentage of positive tumor cell
scores was graded as follows: +++ (strong, 6–7); ++
(moderate, 4–5); + (weak, 2–3); and − (negative, 0–1).
The expression pattern of mutant p53 was also scored
using the combination of staining intensity and the per-
centage of positive tumor cells and simply graded as +
for positive (sum of the score exceeded 3) and − for
negative (2 or less; negative expression or weak expres-
sion in less than 25 % of the cells), in line with previous
reports [10, 17, 18]. At least three different fields under
high magnification (×400) per slide were analyzed for
immunostaining intensity. A summary of the immuno-
histochemical staining results can be found in Table 1.
Statistical analysis and overall survival analysis
The relationship among the expression intensities of
NANOG, mutant p53, and CD44 in OSCC specimens
was statistically evaluated using the chi-squared test.
Similarly, the correlation between the protein expression
patterns and clinicopathological features of OSCC, in-
cluding tumor stage, neck node metastasis, and histo-
logical grade, was also analyzed using the chi-squared
test. The overall survival analysis was conducted using
the Kaplan–Meier method, and the data were compared
Table 1 Summary of clinicopathological features of OSCCs and IHC expression patterns of NANOG, CD44, and mutant p53
NANOG CD44 Mutant p53
Total No. +++ ++ +&– ++ + – + –
No. of cases 57 21 18 18 28 21 8 34 23
Tumor sites
Gingiva 27 13 8 6 10 11 6 13 14
Cheek 4 0 3 1 2 2 0 3 1
Palate 10 4 3 3 9 1 0 10 0
Tongue 9 0 2 7 2 5 2 4 5
FOM 7 4 2 1 5 2 0 4 3
Tumor stage
I + II 24 6 4 14 10 9 5 11 13
III + IV 33 15 14 4 18 12 3 23 10
Neck node
N0 34 9 10 15 13 15 6 16 18
N+ 23 12 8 3 15 6 2 18 5
Histo grade
Well 22 4 4 14 9 9 4 6 16
Mod + Poor 35 17 14 4 19 12 4 28 7
Antibody
Dilution rate 1:250 1:100 1:200
Source (Lot No.) Abcam™ (ab109250) Abcam™ (ab51037) Abcam™ (ab32049)
Abbreviations: FOM floor of mouth, N0 negative neck node, N+ positive neck node, Well well-differentiated OSCC, Mod + Poor moderately and poorly
differentiated OSCC
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using a log-rank test for the 57 OSCC specimens. First,
overall survival analysis was performed in terms of the
treatment modality as well as clinicopathological tumor
features, including tumor stage, neck node metastasis,
and histological grade (Fig. 5a–d). In the present study,
patients were divided according to treatment modalities
into three groups: surgery only (Surg), surgery combined
with adjuvant radiotherapy (Surg + RT, including concur-
rent chemoradiotherapy), and radiotherapy only (RT).
Most patients in the RT group underwent palliative
radiotherapy because they refused to undergo surgery or
their tumors were inoperable. Second, survival analysis
was conducted in terms of the immunostaining inten-
sities of NANOG, mutant p53, and CD44 in the pre-
treatment biopsy specimens (Fig. 5e–h). Univariate and
multivariate survival analyses were performed using a
Cox proportional hazards regression model. All analyses
were performed using IBM SPSS Statistics software
(SPSS Inc., Chicago, IL, USA). The cases were censored
at the date of either the patient’s death or the last fol-
low-up. Results were considered significant at p < 0.05,
and these differences were denoted by an asterisk or
different letters.
Results
Information of patients selected
A total of 57 patients with OSCC consisting of 36 men
and 21 women were included in this study. Patient age
ranged 17–90 years (mean, 65.4 ± 13.9 years). The site of
OSCC in the patients included the gingiva (27 cases),
palate (10 cases), tongue (9 cases), floor of the mouth
(7 cases), and cheek (4 cases) (Table 1). Patients were
divided according to treatment modality as follows: 15
patients in the Surg group, 22 patients in the Surg + RT
group, and 20 patients in the RT group. The mean
follow-up period in all patients was 35.9 months; mean-
while, 24 patients (19, 4, and 1 patient in the RT, Surg +
RT, and Surg groups, respectively) died after an average of
18.4 months, and 33 patients survived over an average fol-
low-up of 48.7 months. In all cases of surgery, resection
tumor margins were set as at least 2 cm, and the resec-
tion field was confirmed to be tumor-free using frozen
biopsy sections.
Expression patterns of NANOG, mutant p53, and CD44 in
OSCC pretreatment biopsy specimens
NANOG was mainly detected in the nuclei of OSCC
cells, but some NANOG expression was detected in the
cytoplasm of cancer cells. Mutant p53 was localized in
the nuclei of cancer cells, whereas CD44 was detected in
the cell membrane of OSCC cells (Fig. 1). The number
of positive cells and the expression intensities were usu-
ally greater in high-grade OSCCs (moderately or poorly
differentiated) than in low-grade tumors (well-differenti-
ated) (Figs. 1 and 2). Of the 57 OSCC specimens, the ex-
pression of NANOG was strong in 21 specimens,
moderate in 18 specimens, and weak or negative in 18
specimens. Moderate, weak, and negative expression of
CD44 was observed in 28, 21, and 8 OSCC specimens, re-
spectively. In addition, 34 specimens were positive for mu-
tant p53, whereas 23 specimens were negative (Table 1).
Direct relationships among the expression intensities
of NANOG, mutant p53, and CD44 were observed
(Fig. 3a). Tumors with strong expression of NANOG
also frequently exhibited positive mutant p53 expression
(p = 0.002) and enhanced CD44 expression (p < 0.001).
Fig. 1 Immunohistochemical staining of NANOG, mutant p53, and CD44 in OSCCs. a Serial sections of moderately differentiated OSCC specimens show
moderate expression of NANOG and CD44, and positive expression of mutant p53. b In higher magnification fields of serial sections, NANOG is detected
mainly in the nuclei but is also expressed in the cytoplasm of some tumor cells. Mutant p53 is detected in the nuclei of tumor cells, while CD44 is
localized in the membranes of cancer cells. The arrows indicate the co-expression sites of NANOG, mutant p53, and CD44 in OSCCs. Scale bar = 50 μm
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Similarly, tumors with positive mutant p53 expression
displayed enhanced expression of CD44 (p < 0.001) (Fig. 3a).
In some cases, co-expression of NANOG, mutant p53, and
CD44 was detected in serial sections of the same OSCC
specimens, indicating that some cancer cells exhibit co-
expression of these three marker proteins. Interestingly,
the co-expression of all three proteins was more frequently
observed in moderately or poorly differentiated OSCCs
(Figs. 1b and 2c).
Association between clinicopathological tumor features
and the expression patterns of NANOG, mutant p53, and
CD44
Strong expression of NANOG was significantly correlated
with histologically high-grade OSCCs (p < 0.001), whereas
weak or negative expression of NANOG predominantly
occurred in well-differentiated carcinomas (p = 0.018).
Similarly, positive mutant p53 expression was significantly
associated with high-grade carcinomas (p < 0.001) (Fig. 3b).
High-grade tumors exhibited enhanced expression of
CD44, but this finding was not statistically significant
(Fig. 3b). In the assessment of the relationship between
protein expression and tumor stage, strong and moderate
expression of NANOG displayed direct associations with
late-stage tumors (stage III and IV; p < 0.05), whereas
weak expression of NANOG was directly associated with
early-stage tumors (stage I and II; p = 0.018) (Fig. 4a).
Positive mutant p53 expression was frequently observed
in late-stage tumors (p = 0.049). Similarly, higher expres-
sion of CD44 was frequently observed in late-stage
tumors, but the difference was not statistically significant
(Fig. 4a). In the analysis of neck node metastasis, weak or
negative expression of NANOG was significantly related
to negative neck node metastasis in OSCCs (p = 0.005)
(Fig. 4b). Similarly, negative expression of mutant p53
(p = 0.007) and weak expression of CD44 (p = 0.049)
were significantly related to a higher frequency of nega-
tive neck node metastasis (Fig. 4b).
Survival analysis
The analysis of overall patient survival rates in terms of
clinicopathological tumor features revealed some sig-
nificant results (Figs. 5a–d). Patients with late-stage
OSCC (stage III and IV) had a statistically significant
lower survival rate than those with early-stage tumors
(Stage I and II) (p < 0.05, Fig. 5a). Patients with OSCC
and positive neck node metastasis displayed a significantly
poorer survival rate than those with negative neck node
metastasis (p < 0.01, Fig. 5b). In addition, patients with
histopathologically high-grade OSCC had a poorer prog-
nosis than those with well-differentiated tumors (p < 0.01,
Fig. 5c). In terms of treatment modality, the RT group
Fig. 2 Immunostaining of well (a & b) and poorly (c) differentiated OSCCs. a In serial sections, the negative expression of NANOG, mutant p53, and
CD44 is detected in one specimen of well-differentiated OSCC (* indicates cancer tissue). b In another case of well-differentiated OSCC, NANOG and
mutant p53 are almost negative, seen in less than 25 % of positive cells, whereas CD44 is weakly detected in the cancer cell membrane (arrows). c In a
poorly differentiated OSCC specimen, enhanced expression of NANOG, mutant p53, and CD44 is detected. The arrows indicate co-localization of the
three marker proteins. Scale bar = 50 μm
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exhibited a significantly poorer survival rate than the Surg
and Surg + RT groups (p < 0.01, Fig. 5d).
Moreover, survival analysis in terms of the immuno-
staining patterns of NANOG, mutant p53, and CD44
revealed statistically significant differences (Figs. 5e–h).
The expression intensity of NANOG was directly associ-
ated with the overall survival rate; patients with strong
NANOG-expressing tumors [NANOG(+++)] had poorer
survival rates than those with weak or negative NANOG-
expressing tumors [NANOG(+/−)] (p < 0.01, Fig. 5e). Simi-
larly, a positive association between mutant p53 expression
and the overall survival rate was observed; specifically,
patients with p53-positive OSCC had lower survival rates
than those with p53-negative OSCC (p < 0.01, Fig. 5f).
Enhanced CD44 expression was associated with poor sur-
vival rates, but this finding was not statistically significant
(p > 0.05, Fig. 5g). Interestingly, patients with co-expression
of enhanced NANOG (moderate or strong expression) and
p53 positivity [NANOG(++)/p53(+)] had significantly
shorter survival rates than patients with weak NANOG
and negative p53 expression [NANOG(+/−)/p53(−)]
(p = 0.014, Fig. 5h). Of significance, among the 28
patients with NANOG(++)/p53(+) tumors, 17 patients
died, whereas there were no deaths in the 12 patients with
NANOG(+/−)/p53(−) lesions during the follow-up period
(Fig. 5h). Univariate Cox proportional hazards regression
analysis revealed that neck node metastasis, histologically
high-grade tumor, and late tumor stage were associated
with significantly poorer prognosis. Moreover, enhanced
expression of NANOG and mutant p53, especially co-
detection of these two proteins, in the OSCC pretreatment
biopsy specimens was directly associated with lower sur-
vival rates (Table 2). Similarly, the multivariate Cox propor-
tional hazards regression model illustrated that neck node
metastasis, histological grade, and immunohistochemical
expression pattern of NANOG were directly related to the
overall survival rate of patients with OSCC (Table 3).
Discussion
Since the emergence of the CSC hypothesis as a key the-
ory to explain cancer progression, the expression patterns
of several pluripotent stem cell markers and transcription
factors have been studied in various cancer tissues or cell
lines to determine their correlation with long-term
Fig. 3 Correlation of the expression patterns of NANOG, mutant p53, and CD44 and the histological grade of OSCCs. a Tumors with enhanced
expression of NANOG show a higher frequency of mutant p53 positivity (p = 0.002) and enhanced CD44 expression (p < 0.001). Similarly, OSCCs
with positive expression of mutant p53 show higher expression of CD44 (p < 0.001). b Strong or moderate expression of NANOG is significantly
related to histopathologically high-grade OSCCs (p < 0.001); however, weak or negative expression of NANOG correlates with well-differentiated
carcinoma (p = 0.018). Moreover, positive mutant p53 expression is significantly associated with high-grade carcinoma (p < 0.001). Similarly,
enhanced CD44 expression is associated with high-grade tumors, but no statistical significance was observed (p = 0.058). Data represent the
number of cases with positive expression of each protein, and an asterisk (*) indicates significant differences (p < 0.05). [Abbreviations: NANOG(++/+++),
strong or moderate expression of NANOG; NANOG(+/−), weak or negative expression of NANOG; p53(+), positive expression of mutant p53; p53(−),
negative expression of mutant p53; CD44(++), more than moderate expression of CD44; CD44(+), weak expression of CD44; CD44(−), negative expression
of CD44; Well, well-differentiated OSCCs; Mod + Poor, moderately and poorly differentiated OSCCs]
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prognosis. In the present study, the early transcription fac-
tor NANOG, the CSC marker CD44, and human mutant
p53 were immunohistochemically investigated in the pre-
treatment biopsy specimens of 57 patients with OSCC to
identify any relationship of their expression patterns with
clinicopathological tumor features and patient prognosis.
The results of this study demonstrated that the immuno-
histochemical expression patterns of NANOG and mu-
tant p53 were directly associated with overall survival
rates as well as clinicopathological features, including
tumor stage, neck node metastasis, and histological
grade. Patients with OSCC whose tumors had higher
expression of NANOG and mutant p53 had less favorable
clinicopathological features and lower survival rates. En-
hanced expression of CD44 was also associated with poor
prognosis and lower survival rates, but no statistical sig-
nificance was observed. Recently, a common modality for
predicting cancer prognosis has been the measurement of
intra-tumor genetic heterogeneity [19, 20]. Heterogeneity
denotes that tumors are composed of multiple clonal sub-
populations of different characteristic cells, and thus,
histological examination frequently reveals differences
in cell morphology and properties, among cells in the
same cancer specimen [20]. Enhanced intra-tumor
heterogeneity was directly correlated with increased
mortality; in particular, high heterogeneity and p53
mutation positivity were associated with higher mor-
tality rates in a large cohort study of head and neck
cancer [19]. In the present study, serial sections of
tumor specimens frequently revealed the co-
expression of NANOG, mutant p53, and CD44, which
was associated with poorer prognosis. The co-
detection of these different marker proteins in the
same cancer cell or same tumor region may represent
high tumor heterogeneity.
NANOG is an early transcription factor and pluripotent
marker that maintains the self-renewal of embryonic and
mesenchymal stem cells [8]. Recent studies revealed that
NANOG is highly detected in poorly differentiated carcin-
omas and late-stage tumors [8–10]. Moreover, a positive
relationship between enhanced NANOG expression and
lymph node metastasis of carcinoma was reported [21].
Similarly, the present study illustrated that strong NANOG
expression was positively correlated with clinically late-
stage and histopathologically high-grade tumors. However,
our findings on the relationship between neck node metas-
tasis and NANOG expression slightly differed from those
observed in previous studies. Weak or negative NANOG
Fig. 4 Correlation of tumor stage or neck node metastasis and the immunostaining patterns of NANOG, mutant p53, and CD44. a Strong or moderate
expression of NANOG is directly associated with late-stage tumors, whereas weak or negative expression of NANOG is directly related to early-stage
carcinoma (p < 0.05). Positive expression of mutant p53 is also significantly associated with late-stage tumors (p = 0.039). Higher expression of CD44 is
frequently associated with late-stage tumors, but no statistical significance was observed (p > 0.05). b Tumors with weak or negative expression of
NANOG (p = 0.004), negative expression of mutant p53 (p = 0.006), and weak expression of CD44 (p = 0.049) show a significantly higher frequency of
negative neck node metastasis. Higher expression levels of the three proteins are not associated with neck node metastasis (p > 0.05). Data represent
the number of cases with positive expression of each protein, and an asterisk (*) indicates a significant difference (p < 0.05). [Abbreviations: I + II, tumor
stage I & II; III + IV, tumor stage III & IV; N0, negative neck node metastasis; N+, positive neck node metastasis]
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Fig. 5 (See legend on next page.)
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expression was associated with negative neck node metas-
tasis, whereas higher NANOG expression was not associ-
ated with positive neck node metastasis in the present
study. In IHC, NANOG is usually detected in the nuclei of
pluripotent cells. However, in the present study, this
transcription-related protein was sometimes observed in
the cell cytoplasm, which is in agreement with previous re-
ports in which NANOG was occasionally detected in the
cytoplasm of highly primitive undifferentiated stem cells or
tumor cells from patients with poor prognoses; these
findings may be related to the pluripotency of stem
cells and invasive or recurrent cancer cells [22, 23]. In
this study, cytoplasmic NANOG expression was usually
detected in high-grade OSCCs (Figs. 1 and 2). In
addition, the overall survival rate was significantly
lower in patients with strong NANOG expression than
in those with weak or negative NANOG expression.
These results suggest that OSCCs with high NANOG
expression, including cytoplasmic expression, may pos-
sess aggressive characteristics, which in turn indicate
poor prognosis.
The wild-type p53 protein is a DNA-binding transcrip-
tion factor that acts as a tumor suppressor by allowing
the cell time to repair and recover from DNA damage or
by inducing cell apoptosis in cases of serious damage
[12, 24]. A review of a large cohort study of OSCC re-
vealed conflicting evidence for p53 as a tumor prognostic
factor; some studies uncovered that positive p53 staining
was associated with poor prognosis, whereas others re-
ported no such association [1]. These contradictory results
may be related to the frequency of mutation of the p53
gene in cancer tissues, particularly carcinomas. Mutant
p53 causes the inactivation and dysfunction of wild-type
p53 and plays a pivotal role in the development and pro-
gression of carcinomas [13, 25]. Co-detection of p53 and
mouse double minute 2 (MDM2) by IHC might be helpful
for discriminating the functional type of p53; high levels
of p53 without increased MDM2 expression may indicate
the inactivating type of p53, usually mutant p53 [17].
Interestingly, mutant p53 is easily detected via immuno-
histochemical analysis [14]. Although wild-type p53 can
also be detected in cancerous tissues using IHC, wild-type
p53 (normally a tumor suppressor gene) may be not re-
lated with poor prognosis of cancer [26, 27]. In the present
study, a human anti-mutant p53 antibody (Abcam™,
ab32049), which does not recognize human wild-type p53
protein but does react with a synthetic peptide corre-
sponding to human mutant p53 aa 1-100 (N terminal),
was used to detect the mutated type of p53 in the pretreat-
ment biopsy specimens of patients with OSCC. A positive
p53 mutation signal was detected in 34 of 57 OSCC speci-
mens (59.6 %). This result supports the finding from a pre-
vious study, which reported a p53 mutation rate of 40–
60 % in carcinoma tissues [1, 17]. In addition, we observed
a positive correlation between high NANOG expression
and mutant p53 positivity: OSCCs with moderate or strongTable 2 Univariate Cox proportional hazards regression analysis
in relation to overall survival of the 57 OSCC patients
Overall survival
Variable P value Hazard ratio 95 % CI
Neck node <0.001* 6.795 2.745–16.817
Histological grade 0.003* 12.271 2.336–64.465
Tumor stage 0.009* 3.718 1.385–9.980
NANOG 0.019* 4.494 1.275–15.839
Mutant p53 0.016* 3.747 1.279–10.977
CD44 0.263 2.315 0.532–10.097
NANOG + p53 0.028* 0.741 0.217–2.531
Abbreviation: CI confidence interval
*Statistically significant (p < 0.05)
Table 3 Multivariate Cox proportional hazards regression
analysis in relation to overall survival of the 57 OSCC patients
Overall survival
Variable P value Hazard ratio 95 % Cl
Neck node 0.004* 6.549 1.800–23.822
Histological grade 0.012* 3.598 1.330–9.937
Tumor stage 0.254 3.546 0.403–31.225
NANOG 0.035* 4.319 3.351–27.476
Mutant p53 0.180 1.195 1. 713–5.754
Abbreviation: CI confidence interval
*Statistically significant (p < 0.05)
(See figure on previous page.)
Fig. 5 The overall survival rate of OSCC patients according to clinicopathological tumor features, treatment modality, and immunostaining patterns of
NANOG, mutant p53, and CD44. a Patients with late-stage tumors (stage III & IV) show significantly poorer survival rates (p < 0.05). b–d A positive
association between the overall survival rate of OSCC patients and histopathological tumor grade, neck node metastasis, and treatment
modality is observed. The well-differentiated OSCC group, negative neck node group, and surgical treatment group show significantly better
long-term survival rates than the corresponding opposite groups (p < 0.01). e Enhanced expression of NANOG is associated with a poor survival rate; in
particular, patients with strong or moderate expression of NANOG show significantly lower survival rates than those with weak or negative NANOG
expression (p < 0.01). f Patients with mutant p53(+)-expressing tumors show a lower survival rate than those with tumors negative for mutant p53(−)
(p < 0.01). g Enhanced CD44 expression tends to correlate with poor survival rates, but no statistical significance was found (p > 0.05). h OSCCs with
co-expression of enhanced NANOG and mutant p53 [NANOG(++)/p53(+)] correlate with a significantly lower overall survival rate than those with weak
NANOG and p53 negativity [NANOG(+/−)/p53(−)] (p = 0.014). Notably, there were no deaths in the 12 cases of NANOG(+/−)/p53(−) during the follow-
up period. Different letters denote statistically significant differences between groups (p < 0.05)
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expression of NANOG had a higher frequency of p53 mu-
tation (Fig. 3a). In addition, OSCCs that expressed mutant
p53 were more frequently high-grade tumors (Fig. 3b),
whereas tumors that were negative for mutant p53 were
associated with fewer neck node metastases (Fig. 4b).
Moreover, patients with p53 mutations had a significantly
poorer survival rate than those without p53 mutations
(Fig. 5f). Interestingly, the co-detection of an enhanced
NANOG signal and mutant p53 [NANOG(++)/p53(+)]
was correlated with significantly lower patient survival ver-
sus tumors with weak NANOG expression and p53 nega-
tivity [NANOG(+/−)/p53(−)] (Fig. 5h).
CD44 is a cell surface glycoprotein that acts as a re-
ceptor for hyaluronic acid and as an adhesion molecule
[7, 28]. This cell surface protein plays a role in tumor
cell invasion, metastasis, and angiogenesis by interacting
with certain matrix metalloproteinases [29]. CD44 was first
described as a CSC marker in breast cancer and HNSCC
[4, 5], and it has since been used as a CSC marker and
prognostic factor for SCC [11, 30]. CD44 has exhibited
positive correlations with tumor recurrence, high-grade
SCCs, and poor prognosis [30]. However, its limited useful-
ness as a CSC marker or prognostic factor in OSCC was
also reported [31, 32]. In the present study, OSCCs that
expressed high levels of NANOG and mutant p53 also
displayed significantly elevated expression of CD44 (Fig. 3a).
In addition, high CD44 expression was associated with
clinically late-stage and histologically high-grade tumors,
although no statistical significance was found in this ana-
lysis. Only the group with weak CD44 expression displayed
a statistically higher frequency of negative neck node
metastasis (Fig. 4b). However, in this study, the CD44
expression pattern was not statistically correlated with
overall survival rates, but high expression of CD44 tended
to be associated with poor prognosis (Fig. 5g). These re-
sults indicate that CD44 expression could have limited use
as a clinicopathological and prognostic marker for OSCC,
as suggested in previous reports [28, 32].
In this study, overall survival rates were analyzed in
terms of the clinicopathological features of OSCCs as
well as the immunohistochemical expression patterns of
the three marker proteins. In the Kaplan-Meier analysis
with the log-rank test, patients with late-stage tumors,
positive neck node metastases, and high histopatho-
logical grade tumors had significantly lower survival
rates. Similar results were obtained by univariate and
multivariate Cox proportional hazards regression ana-
lysis for overall survival of the 57 patients with OSCC.
Neck node metastasis, histological grade, tumor stage,
and the expression intensity of NANOG and mutant
p53 were directly associated with the overall survival
rate of the patients; however, the relationship between
survival and the expression pattern of mutant p53 was
not statistically significant in multivariate Cox analysis
(Tables 2–3). In the three groups as divided treatment
modality, the RT group displayed a much poorer prog-
nosis than the Surg or Surg + RT group (Fig. 5d). This
result is likely attributable to the characteristics of the
patients in the RT group, as palliative radiotherapy is se-
lected as a treatment option in cases of tumor inoper-
ability or patient refusal to undergo surgery.
Conclusions
Although this study has a limited number of cases and
used only IHC in paraffin-embedded tissue specimens, the
results suggest that co-detection of mutant p53 and high
NANOG levels in the pretreatment biopsy specimens of
patients with OSCC is directly associated with unfavorable
clinicopathological tumor features and poor survival rates.
The enhanced expression of CD44 also displayed a limited
correlation with clinically late-stage and histopathologic-
ally high-grade OSCCs. Taken together, the immunohisto-
chemical expression patterns of NANOG, mutant p53,
and CD44 in pretreatment biopsy specimens could be
used as predictive markers for prognosis and tumor ag-
gressiveness in patients with OSCC. Particularly, analysis
for co-expression of NANOG and mutant p53 could be
used as a tool for prognosis and for selecting individual
treatment modalities.
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